First Patient Dosed in IDeate-Lung02 Trial for Relapsed SCLC

In the IDeate-Lung02 Phase 3 trial, which compares the use of chemotherapeutic agents prescribed by a physician to investigational ifinatamab deruxtecan (I-DXd) for patients with relapsed small cell lung cancer (SCLC), Daiichi Sankyo and Merck have announced that the first patient has received a dose. Specifically tailored, ifinatamab deruxtecan is a cooperatively developed antibody-drug combination (ADC) by Merck and Daiichi Sankyo that has the potential to be the first-in-class B7-H3 directed DXd. With 15% of cases, small cell lung cancer (SCLC) is the second most prevalent kind of lung cancer. Adversive small cell lung cancer (SCLC) advances quickly to the metastatic stage and has a three-year survival rate.
A moderate-to-high expression of the protein B7-H3, linked to poor prognosis and disease progression, is present in around 65% of all SCLC tumours.